［1］HAIDER T,TIWARI R,VYAS SP,et al.Molecular determinants as therapeutic targets in cancer chemotherapy:An update［J］.Pharmacology & Therapeutics (Oxford),2019,200:85-109.
［2］BEN-HAMO R,EFRONI S.MicroRNA regulation of molecular pathways as a generic mechanism and as a core disease phenotype［J］.Oncotarget,2015,6(3):1594-1604.
［3］AMBROS V.The functions of animal microRNAs［J］.Nature，2004，431(7006)：350-355.
［4］KIM VN.MicroRNA biogenesis：Coordinated cropping and dicing［J］.Nature Reviews Molecular Cell Biology，2005，6(5)：376-385.
［5］VAN KOUWENHOVE M，KEDDE M，AGAMI R.MicroRNA regulation by RNA-binding proteins and its implications for cancer［J］.Nature Reviews Cancer，2011，11(9)：644-656.
［6］ZHU D，LI X，QI Y，et al.MiR-454 promotes the progression of human non-small cell lung cancer and directly targets PTEN［J］.Biomedicine & Pharmacotherapy，2016，81：79-85.
［7］HUNTZINGER E，IZAURRALDE E.Gene silencing by microRNAs：Contributions of translational repression and mRNA decay［J］.Nature Reviews Genetics，2011，12(2)：99-110.
［8］KROL J，LOEDIGE I，FILIPOWICZ W.The widespread regulation of microRNA biogenesis，function and decay［J］.Nature Reviews Genetics，2010，11(9)：597-610.
［9］RODEN C，GAILLARD J，KANORIA S，et al.Novel determinants of mammalian primary microRNA processing revealed by systematic evaluation of hairpin-containing transcripts and human genetic variation［J］.Genome Research，2017，27(3)：374-384.
［10］WAHID F，SHEHZAD A，KHAN T，et al.MicroRNAs：Synthesis，mechanism，function，and recent clinical trials［J］.Biochimica et Biophysica Acta(BBA)-Molecular Cell Research，2010，1803(11)：1231-1243.
［11］CULLEN BR.Transcription and processing of human microRNA precursors［J］.United States：Elsevier Inc，2004，16(6)：861-865.
［12］HAN J，CHOI H，KIM VN，et al.The nuclear RNase III Drosha initiates microRNA processing［J］.Nature，2003，425(6956)：415-419.
［13］ZHANG B，WANG Q，PAN X.MicroRNAs and their regulatory roles in animals and plants［J］.Journal of Cellular Physiology，2007，210(2)：279-289.
［14］ZHANG X，ZENG Y.The terminal loop region controls microRNA processing by Drosha and Dicer［J］.Nucleic Acids Research，2010，38(21)：7689-7697.
［15］WEN SH，STOLAROV J，MYERS MP，et al.PTEN controls tumor-induced angiogenesis［J］.Proceedings of the National Academy of Sciences of the United States of America，2001，98(8)：4622-4627.
［16］JIN C，LIN T，SHAN L.Downregulation of calbindin 1 by miR-454-3p suppresses cell proliferation in nonsmall cell lung cancerin vitro［J］.Cancer Biotherapy and Radiopharmaceuticals，2019，34(2)：119-127.
［17］GRZYBOWSKA E.Calcium-binding proteins with disordered structure and their role in secretion，storage，and cellular signaling［J］.Biomolecules，2018，8(2)：42.
［18］OMURO A，DEANGELIS LM.Glioblastoma and other malignant gliomas：A clinical review［J］.JAMA，2013，310(17)：1842-1850.
［19］FANG B，ZHU JX，WANG YH，et al.MiR-454 inhibited cell proliferation of human glioblastoma cells by suppressing PDK1 expression［J］.Biomedicine & Pharmacotherapy，2015，75：148-152.
［20］FALASCA M，FYFFE C.3-phosphoinositide-dependent protein kinase-1 as an emerging target in the management of breast cancer［J］.Cancer Management and Research，2013，5：271-280.
［21］PAN MG，XIONG Y，CHEN F.NFAT gene family in inflammation and cancer［J］.Current Molecular Medicine，2013，13(4)：543.
［22］ZUO J，YU HM，XIE P，et al.miR-454-3p exerts tumor-suppressive functions by down-regulation of NFATc2 in glioblastoma［J］.Gene，2019，710：233-239.
［23］MALUCCIO M，COVEY A.Recent progress in understanding，diagnosing，and treating hepatocellular carcinoma［J］.CA：A Cancer Journal for Clinicians，2012，62(6)：394-399.
［24］YU L，GONG XJ，SUN L，et al.miR-454 functions as an oncogene by inhibiting CHD5 in hepatocellular carcinoma［J］.Oncotarget，2015，6(36)：39225-39234.
［25］KOLLA V，ZHUANG TG，HIGASHI M，et al.Role of CHD5 in human cancers：10 years later［J］.Cancer Research，2014，74(3)：652-658.
［26］LI YQ，JIAO Y，FU Z，et al.High miR-454-3p expression predicts poor prognosis in hepatocellular carcinoma［J］.Cancer Management and Research，2019，11：2795-2802.
［27］SONG Y，GUO QS，GAO SJ，et al.MiR-454-3p promotes proliferation and induces apoptosis in human cervical cancer cells by targeting TRIM3［J］.Biochemical and Biophysical Research Communications，2019，516(3)：872-879.
［28］HUANG XQ，ZHANG XF，XIA JH，et al.Tripartite motif-containing 3(TRIM3) inhibits tumor growth and metastasis of liver cancer［J］.Chin J Cancer，2017，36(1)：77.
［29］GUO Y，TAO M，JIANG M.MicroRNA-454-3p inhibits cervical cancer cell invasion and migration by targeting c-Met［J］.Experimental and Therapeutic Medicine，2018，15(3)：2301-2306.
［30］ORGAN SL，TSAO MS.An overview of the c-MET signaling pathway［J］.Ther Adv Med Oncol，2011，3(1 Suppl)：S7-S19.
［31］NUSSE R，Clevers H.Wnt/β-catenin signaling，disease，and emerging therapeutic modalities［J］.Cell，2017，169(6)：985-999.
［32］REN LL，CHEN H，SONG JW，et al.MiR-454-3p-Mediated wnt/β-catenin signaling antagonists suppression promotes breast cancer metastasis［J］.Theranostics，2019，9(2)：449-465.
［33］WANG SG，ZHANG G，ZHENG WX，et al.MiR-454-3p and miR-374b-5p suppress migration and invasion of bladder cancer cells through targetting ZEB2［J］.Bioscience Reports，2018，38(6)：R20181436.
［34］ZHANG YJ，LIN S，CHEN Y，et al.LDH-A promotes epithelial & ndash,mesenchymal transition by upregulating ZEB2 in intestinal-type gastric cancer［J］.NCBI,2018，11：2363-2373.
［35］WU X，DING N，HU WT，et al.Down-regulation of BTG1 by miR-454-3p enhances cellular radiosensitivity in renal carcinoma cells［J］.Radiat Oncol，2014，9：179.
［36］MATSUDA S，ROUAU LTJ，MAGAUD J，et al.In search of a function for the TIS21/PC3/BTG1/TOB family［J］.Febs Letters，2001，497(2/3)：67-72.
［37］DONG PX，XIONG Y，YUE JM，et al.Long noncoding RNA NEAT1 drives aggressive endometrial cancer progression via miR-361-regulated networks involving STAT3 and tumor microenvironment-related genes［J］.Journal of Experimental & Clinical Cancer Research，2019，38(1)：295.
［38］XIA Y，ZHOU Y，HAN H，et al.lncRNA NEAT1 facilitates melanoma cell proliferation，migration，and invasion via regulating miR-495-3p and E2F3［J］.Journal of Cellular Physiology，2019，234(11)：19592-19601.
［39］GUO SE，CHEN WJ，LUO YH，et al.Clinical implication of long non-coding RNA NEAT1 expression in hepatocellular carcinoma patients［J］.Int J Clin Exp Pathol，2015，8(5)：5395-5402.
［40］JIANG DT，LI H，XIANG HP，et al.Long chain non-coding RNA(lncRNA) HOTAIR knockdown increases miR-454-3p to suppress gastric cancer growth by targeting STAT3/cyclin D1［J］.Medical Science Monitor，2019，25：1537-1548.
［41］ZHAO X，LI X，ZHOU L，et al.LncRNA HOXA11-AS drives cisplatin resistance of human LUAD cells via modulating miR-454-3p/Stat3［J］.Cancer Science，2018，109(10)：3068-3079.
［42］WAKE MS，WATSON CJ.STAT3 the oncogene-still eluding therapy［J］.FEBS Journal，2015，282(14)：2600-2611.